AbbVie’s Stalling Tactics On Humira Pay Off – In More Ways Than One
A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.
You may also be interested in...
US Senate hearing on pharmaceutical competition brought renewed interest to idea of pruning so-called ‘patent thickets.’ But the choking growth of legislative proposals may itself by hampering progress on Capitol Hill.
Of the 14 leading biopharma companies, only AstraZeneca and Roche spent more on R&D than on buybacks and dividends over the past five years, the report from the US House Committee on Oversight and Reform shows.
Industry chiefs and experts, including Sandoz' global head of biopharmaceuticals, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.